Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: Evidence for modulation of interferon signaling pathways by interleukin-12

被引:19
作者
Eisenbeis, CF
Lesinski, GB
Anghelina, M
Parihar, R
Valentino, D
Liu, J
Nadella, P
Sundaram, P
Young, DC
Sznol, M
Walker, MJ
Carson, WE
机构
[1] Ohio State Univ, Dept Surg, Div Surg Oncol, Columbus, OH 43210 USA
[2] Ohio State Univ, Div Hematol & Oncol, Columbus, OH 43210 USA
[3] Ohio State Univ, Div Human Canc Genet, Columbus, OH 43210 USA
[4] Ohio State Univ, Arthur G James Canc Hosp, Ctr Biostat, Columbus, OH 43210 USA
[5] Ohio State Univ, Richard J Solove Res Inst, Columbus, OH 43210 USA
[6] Yale Univ, New Haven, CT 06520 USA
关键词
D O I
10.1200/JCO.2005.02.1691
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To evaluate the safety of sequentially administered recombinant (r) human (h) interleukin-12 (IL-12) and interferon alfa-2b (IFN-alpha-2b) in patients with advanced cancer and to determine the effects of endogenously produced IFN-gamma on Janus kinase-signal transducer and activator of transcription (Jak-STAT) signal transduction in patient peripheral-blood mononuclear cells (PBMCs). Patients and Methods Forty-nine patients with metastatic cancer received rhIL-12 on day 1 and IFN-a-2b on days 2 to 6 of either a 14-day (n = 43) or a 7-day treatment cycle (n = 6). rhIL-12 was initially administered subcutaneously at a dose of 100 ng/kg, whereas IFN-alpha-2b was escalated from 1 to 10 million units (MU) in cohorts of three patients (1, 3, 5, 7, or 10 MU). rhIL-12 was subsequently administered intravenously (IV) in escalating doses (100 to 500 ng/kg) to achieve greater IFN-gamma production. Peripheral blood was drawn for measurement of plasma IFN-gamma and the induction of Jak-STAT signal transduction in PBMCs. Results No IL-12- or IFN-alpha-related dose-limiting toxicities were observed. There were no responses in 41 assessable patients. Five patients exhibited stable disease lasting 6 months or longer while on therapy. Optimal induction of IFN-gamma by IL-12 occurred after an IV dose of 250 ng/kg. Patient PBMCs exhibited increased levels of STAT1 after IL-12 administration. The peak level of IFN-gamma achieved with IL-12 therapy correlated with the peak level of intracellular STAT1 in patient PBMCs (r = 0.38, P = .021). Conclusion The combination of rhIL-12 and IFN-a-2b can be administered sequentially with minimal toxicity. IV administration of rhIL-12 modulates IFN-alpha-induced Jak-STAT signal transduction in patient PBMCs.
引用
收藏
页码:8835 / 8844
页数:10
相关论文
共 50 条
[11]   A PHASE-IA TRIAL OF SEQUENTIAL ADMINISTRATION RECOMBINANT DNA-PRODUCED INTERFERONS - COMBINATION RECOMBINANT INTERFERON-GAMMA AND RECOMBINANT INTERFERON-ALPHA IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA [J].
ERNSTOFF, MS ;
NAIR, S ;
BAHNSON, RR ;
MIKETIC, LM ;
BANNER, B ;
GOODING, W ;
DAY, R ;
WHITESIDE, T ;
HAKALA, T ;
KIRKWOOD, JM .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (10) :1637-1649
[12]   Detection of intracellular phosphorylated STAT-1 by flow cytometry [J].
Fleisher, TA ;
Dorman, SE ;
Anderson, JA ;
Vail, M ;
Brown, MR ;
Holland, SM .
CLINICAL IMMUNOLOGY, 1999, 90 (03) :425-430
[13]   The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses [J].
Gately, MK ;
Renzetti, LM ;
Magram, J ;
Stern, AS ;
Adorini, L ;
Gubler, U ;
Presky, DH .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :495-521
[14]   Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma [J].
Gollob, JA ;
Veenstra, KG ;
Parker, RA ;
Mier, JW ;
McDermott, DF ;
Clancy, D ;
Tutin, L ;
Koon, H ;
Atkins, MB .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2564-2573
[15]   Intramuscular electroporation delivery of IL-12 gene for treatment of squamous cell carcinoma located at distant site [J].
Hanna, E ;
Zhang, XJ ;
Woodlis, J ;
Breau, R ;
Suen, J ;
Li, SL .
CANCER GENE THERAPY, 2001, 8 (03) :151-157
[16]   IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice [J].
Harada, N ;
Shimada, M ;
Okano, S ;
Suehiro, T ;
Soejima, Y ;
Tomita, Y ;
Maehara, Y .
JOURNAL OF IMMUNOLOGY, 2004, 173 (11) :6635-6644
[17]  
Hatina J, 1996, EXP CLIN IMMUNOGENET, V13, P55
[18]   PHASE-I STUDY OF A COMBINATION OF RECOMBINANT INTERFERON-ALPHA AND RECOMBINANT INTERFERON-GAMMA IN CANCER-PATIENTS [J].
KURZROCK, R ;
ROSENBLUM, MG ;
QUESADA, JR ;
SHERWIN, SA ;
ITRI, LM ;
GUTTERMAN, JU .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (11) :1677-1683
[19]   Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials [J].
Lens, MB ;
Dawes, M .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1818-1825
[20]   Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy [J].
Lesinski, GB ;
Valentino, D ;
Hade, EM ;
Jones, S ;
Magro, C ;
Chaudhury, AR ;
Walker, MJ ;
Carson, WE .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (09) :815-825